CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dec. 27, 2021—Quidel and Ortho Clinical Diagnostics have entered into a definitive agreement in which Quidel will acquire Ortho for $24.68 per share of common stock for a total consideration of about $6 billion. The transaction is expected to close during the first half of fiscal year 2022, subject to customary closing conditions.
“By bringing together Quidel’s point-of-care diagnostics with Ortho’s vast global reach, there is a substantial opportunity to capitalize on the cross-selling opportunities, move into attractive adjacent markets, and accelerate innovative product expansion and the development of molecular technologies,” Chris Smith, chairman and CEO of Ortho, said in a joint press statement. “Together, we will continue to advance life-changing diagnostic solutions to improve patient outcomes and deliver economic benefits to the health care system.”